Entity

Time filter

Source Type

Palo Alto, CA, United States

Guilford F.T.,Your Energy Systems LLC | Hope J.,Environmental Medicine LLC
Toxins | Year: 2014

Evidence for the role of oxidative stress in the pathophysiology of mycotoxin-related illness is increasing. The glutathione antioxidant and detoxification systems play a major role in the antioxidant function of cells. Exposure to mycotoxins in humans requires the production of glutathione on an "as needed" basis. Research suggests that mycotoxins can decrease the formation of glutathione due to decreased gene expression of the enzymes needed to form glutathione. Mycotoxin-related compromise of glutathione production can result in an excess of oxidative stress that leads to tissue damage and systemic illness. The review discusses the mechanisms by which mycotoxin-related deficiency of glutathione may lead to both acute and chronic illnesses. © 2014 by the authors; licensee MDPI, Basel, Switzerland. Source


The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinsons disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.


The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on


The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with ACE inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with lisinopril in particular.


Patent
Emory University, Your Energy Systems Llc and Children's Healthcare Of Atlanta | Date: 2014-02-14

The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on

Discover hidden collaborations